Compare CANG & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CANG | NYXH |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.5M | 137.5M |
| IPO Year | 2018 | 2021 |
| Metric | CANG | NYXH |
|---|---|---|
| Price | $1.29 | $0.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $5.70 | $2.78 |
| AVG Volume (30 Days) | ★ 2.4M | 225.9K |
| Earning Date | 11-30-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $247.05 |
| Revenue Next Year | $30.96 | $99.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.80 |
| 52 Week High | $4.13 | $5.92 |
| Indicator | CANG | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 34.25 | 29.25 |
| Support Level | $0.27 | $0.80 |
| Resistance Level | $2.19 | $1.69 |
| Average True Range (ATR) | 0.37 | 0.06 |
| MACD | -0.18 | 0.00 |
| Stochastic Oscillator | 4.53 | 16.67 |
Cango Inc is a Bitcoin mining company with a vision to establish an integrated, world-wide infrastructure platform capable of powering the future digital economy. The operations are divided into two reportable segments (i) Bitcoin Mining Business and (ii) International Automobile Trading Business. The Company's mining operations span over 40 sites across North America, the Middle East, South America, and East Africa. Since entering the digital asset space in November 2024, Cango has activated pilot projects in both integrated energy solutions and distributed AI computing. In parallel, Cango continues to operate an online international used car export business through its subsidiary.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.